Grb2-associated binder 2 (Gab2) is a recently identified member of the Gab/Daughter of sevenless family of docking proteins, which localize, amplify and integrate signaling pathways activated by various receptors including receptor tyrosine kinases (RTKs). To date, Gab2 signaling has been primarily investigated in hematopoietic cells. Here we report marked overexpression of Gab2 in a subset of breast cancer cell lines relative to normal breast epithelial strains and a trend for increased Gab2 expression in estrogen receptor (ER)-positive lines. Overexpression relative to normal ductal epithelium was also observed in some primary breast cancers. In MCF-7 breast cancer cells Gab2 was markedly tyrosine phosphorylated in response to heregulin and also following EGF, insulin or bFGF administration, indicating that a variety of RTKs implicated in breast cancer development or progression couple to this docking protein. In hormone-responsive breast cancer cells, GAB2 mRNA and protein expression were induced by estradiol in a manner sensitive to the pure anti-estrogen ICI 182780, indicating that this regulation is mediated via the ER. Gab2 therefore represents a novel link between steroid and growth factor signaling in breast cancer, and when overexpressed, may modulate the sensitivity of breast cancer cells to these important growth regulators. Oncogene (2002) 21, 5175 -5181. doi:10.1038/sj.onc. 1205522
Keywords: tyrosine kinase; growth factors; steroid hormones; signal transduction; breast cancer Specific steroid hormones, which signal through members of the nuclear receptor superfamily of ligand-regulated transcription factors, and a variety of polypeptide hormones, which bind cell surface receptor tyrosine kinases (RTKs), play major roles in the development and progression of human breast cancer (Clarke, 2000; Hynes, 2000) . However, it is now evident that there is extensive crosstalk between the steroid and growth factor signaling networks. Cell cycle control represents one level at which estrogens and growth factors synergize to stimulate the proliferation of breast cancer cells. Co-administration of estradiol and insulin/IGF-1 leads to a synergistic increase in S phase fraction compared to addition of either alone, since estradiol, by inhibiting the insulininduced increase in the expression of the cyclindependent kinase (Cdk)-inhibitor p21, enhances formation of high activity cyclin E-Cdk2 complexes (Lai et al., 2001) . A second level is by steroid-induced increases in the expression of particular growth factors e.g. TGF-a and IGF-II, or components of their signaling pathways e.g. IGF-IR (Bates et al., 1988; Yee and Lee, 2000) . Finally, direct ligand-dependent activation of particular cytoplasmic signaling pathways by the estrogen receptor (ER) has also been demonstrated. For example, estrogen activates the Ras/ mitogen-activated protein kinase (MAPK) cascade through c-Src-mediated Shc tyrosine phosphorylation (Migliaccio et al., 1996) . However, the contribution of the latter class of events to cell cycle control is controversial.
Importantly, crosstalk between growth factor and steroid receptor signaling is bidirectional. For example, the extracellular signal-regulated kinase (Erk) family of MAPKs and protein kinase B increase the activity of ERa through phosphorylation of the N-terminal activation function-1 domain (Kato et al., 1995; Campbell et al., 2001) . Such observations have led to the hypothesis that increased activity of particular growth factor signaling pathways might lead to decreased estrogen sensitivity of breast cancer cells and ultimately antiestrogen resistance (Campbell et al., 2001; Ali and Coombes, 2000; Kurokawa et al., 2000) . Signaling proteins which contribute to anti-estrogen resistance may therefore provide useful prognostic indicators for risk of relapse on such therapies, identifying patients who might benefit from more aggressive treatment regimes.
The recent observation that insulin receptor substrate (IRS)-1 expression is estrogen regulated and associated with early disease recurrence in ER-positive breast cancers (Lee et al., 1999) led us to investigate the expression and regulation of related proteins in breast cancer cells. Docking proteins such as IRS-1-4, fibroblast growth factor receptor substrate (FRS)-2 and Grb2-associated binder (Gab)1-3 are characterized by a N-terminal motif or domain for plasma membrane association e.g. a myristoylation sequence in FRS2 or a pleckstrin homology (PH) domain in Gab and IRS proteins, and multiple tyrosine phosphorylation sites to enable recruitment of specific signaling proteins (Yenush and White, 1997; Kouhara et al., 1997; Holgado-Madruga et al., 1996; Gu et al., 1998; Wolf et al., 2002) . Docking proteins thereby act as assembly platforms and are likely to perform important roles in signal integration and targeting signaling events to particular cellular locations. In Drosophila, genetic studies indicate that DOS signals downstream of the RTK Sevenless and is a binding target and substrate of the Shp-2 homolog Corkscrew, which functions either parallel to, or both upstream and downstream, of Ras . Sequence similarity and domain organization indicate that Gab1-3 are higher organism homologues of DOS (Gu et al., 1998; Wolf et al., 2002) . Most work to date on Gab2 has focused on responses triggered by antigen receptors or cytokines, and coupling of Gab2 to Shp-2 regulates a novel pathway leading to cytokine-induced immediate-early gene transcription (Gu et al., 1998) . Tyrosine-phosphorylated Gab1 and Gab2 associate with a variety of signaling proteins including Grb2, the p85 subunit of phosphatidylinositol (PI)3-kinase, Shc and Shp-2 (Holgado- Madruga et al., 1996; Gu et al., 1998) , thereby playing key roles in activating and integrating the Ras and PI3-kinase pathways.
However, despite the importance of Gab proteins in RTK signaling, their expression and regulation in human epithelial malignancies has yet to be characterized. We therefore examined the expression profile of Gab2 in normal or immortalized breast epithelial cells and a wide panel of breast cancer cell lines by Western blot analysis (Figure 1a,b) . Gab2 was expressed at low levels in the normal breast epithelial cell strains 184 and HMEC-219-4 and the immortalized 184 derivatives 184A1 and 184B5. However, a subset of the breast cancer cell lines exhibited marked overexpression of Gab2 relative to the normal or immortalized cells. Using a Chi-square test in which Gab2 is dichotomised at the median value for the breast cancer lines of 0.716, there is a trend for increased Gab2 expression in ERpositive lines (P=0.0578), although this does not reach statistical significance. The varying mobility of Gab2 isolated from different cell lines is probably due to different degrees of serine/threonine phosphorylation, which represents an additional mechanism for regulating Gab2 signaling (Lynch and Daly, 2002) . In contrast, Gab1 was expressed at relatively high levels in the normal breast epithelial strain 184 and its immortalized derivative 184B5, and also in the majority of the breast cancer cell lines. Consequently, -219-4 ) and the immortalized 184 derivatives (184A1 and 184B5) were cultured as described previously (Buckley et al., 1993) . Briefly, breast cancer cell lines were cultured in 10% FCS/RPMI 1640 medium supplemented with 10 mg/ml insulin. Normal/immortalized breast epithelial cells were cultured in MCDB medium 170 supplemented with 1% bovine pituitary extract (both from Invitrogen). All cell lines/strains were harvested while in exponential phase. Preparation of cell lysates, protein estimations and Western blots were performed as described in Janes et al. (1994) . Cell lysates (40 mg protein) were subjected to Western blot analysis with antibodies specific for Gab2 (Santa Cruz Biotechnology sc-9313) (top panel), Gab1 (Upstate Biotechnology 06-579) (middle panel) or b-actin (Sigma Clone AC-15) (lower panel). Visualization of bound antibodies was by enhanced chemiluminescence (ECL). (b) Analysis of Gab2 expression in normal/immortalized breast epithelial strains and breast cancer cell lines. Densitometric analysis was performed on the Gab2 and actin Western blots shown in (a) using IP Lab Gel software (Signal Analytics). The histogram shows Gab2 levels normalized for actin expression. (c) Expression of GAB2 mRNA. Total RNA was isolated from a selection of the above cell strains/lines according to preparation kit procedure (Qiagen) and then subjected to Northern blotting as previously described (Alexander et al., 1989) . Each lane contained 20 mg of RNA, and equivalent loading was confirmed by ethidium bromide staining. A partial human GAB2 cDNA (designated KIAA0571, clone HH02388) (Zhao et al., 1999) in pBluescript II SK + was obtained from the Kazusa DNA Research Institute (Chiba, Japan). The probe utilized for Northern blotting was a 1748 bp SphI -KpnI fragment spanning nucleotides 3885 -5633 labeled by random primer extension (Promega) using a- Gab1 and Gab2 exhibit different expression profiles among breast cancer cell lines; only Gab2 is clearly overexpressed in cancer lines relative to normal or immortalized cells, and there is a trend for Gab2 to be more highly expressed in ER-positive lines.
In order to investigate the mechanism for Gab2 overexpression in breast cancer cell lines, Northern blot analysis was performed ( Figure 1c ). Expression of GAB2 mRNA closely paralleled that of Gab2 protein, with undetectable levels in the normal breast epithelial strain HMEC-219-4 and the immortalized breast epithelial lines 184A1 and 184B5, and high expression in the majority of the ER-positive lines but only in a small subset (MDA-MB-231 and -468) of the ERnegative lines. Therefore, enhanced GAB2 mRNA expression represents a major mechanism underlying Gab2 overexpression in breast cancer cells.
To characterize Gab2 expression in normal and malignant breast tissue, immunohistochemical analysis was performed (Figure 2) . Paraffin-embedded cell pellets of the MDA-MB-231 cell line showed cytoplasmic staining (Figure 2a) while BT-549 cell pellets scored negative (data not shown), in agreement with the expression data (Figure 1 ). Six specimens of normal breast tissue were examined of which two were negative for Gab2 and 4 demonstrated only weak staining of the normal ductal epithelium (Figure 2b ). Three ERnegative breast cancer cases were examined and all scored negative for Gab2 (Figure 2c ). Two ductal carcinoma in situ specimens were also ER-negative and Figure 2 Expression of Gab2 in the normal breast and in primary breast cancers. Gab2 expression was characterized by immunohistochemistry on sections derived from paraffin blocks of formalin-fixed breast tissue specimens. Paraffin-embedded cell pellets of breast cancer cell lines of known Gab2 status, MDA-MB-231 and BT-549, were used as positive and negative controls, respectively, while the same cell pellet of MDA-MB-231 cells incubated in diluent without antibody was the negative technical control. The sections were dewaxed and rehydrated prior to unmasking in a commercial, low pH target retrieval solution (DAKO Corporation), and incubated with 1 : 100 Gab2 antibody (Santa Cruz Biotechnology sc-9313). A streptavidin-biotin peroxidase detection system was used according to the manufacturer's instructions (Large Volume DAKOLSAB+ Kit, DAKO Corporation), with 3,3'-diaminobenzidine as substrate. Counterstaining was performed with Whitlock's hematoxylin. Immunostaining was initially assessed by one investigator (SM Henshall) and subsequently reviewed independently by a histopathologist. For each slide, the percentage of Gab2 immunostaining within areas of cancer, DCIS and normal breast tissue was expressed as the ratio of Gab2-positive cells to the total number of cells counted. Levels of Gab2 expression were classified as positive (450% immunoreactivity) or negative (450% immunoreactivity). This cut-off was based on the median levels of Gab2 expression detected in areas of normal breast ductal epithelium that was calculated as 50%. The panels show representative photomicrographs of Gab2 expression detected by immunohistochemistry. (a) Paraffin-embedded cell pellets of the breast cancer cell line MDA-MB-231, staining positively for Gab2. (b) Gab2 expression in the ductal epithelium of normal breast tissue (6200). (c) A specimen of ER-negative breast cancer showing no immunoreactivity for Gab2 (6200). (d) Gab2 immunoreactivity in an ER-positive breast cancer specimen (6200). The inset shows a region of this specimen viewed at higher magnification (6400) to highlight the cytoplasmic staining for Gab2 scored negative for Gab2 (data not shown). In contrast, four of the seven (57%) ER-positive breast cancer specimens examined were Gab2-positive at a cut-off of 450% positive cells. Furthermore, the ERpositive specimens tended to exhibit an increased intensity of staining compared with normal breast and ER-negative sections (Figure 2d ). Where present, staining was cytoplasmic in all specimens (Figure 2d,  inset) . Therefore, in agreement with the data from cell culture models, Gab2 is overexpressed in a subset of primary breast cancers compared to normal mammary epithelium. Also, the results are consistent with an association between Gab2 expression and ER positivity, although this relationship needs to be confirmed through analysis of a larger patient cohort.
To date, research on the signaling role of Gab2 has largely focused on hematopoietic cells (Gu et al., 1998) . Since Gab2 is expressed at high levels in a subset of breast cancer cell lines (Figure 1 ) and primary breast cancers (Figure 2) , it is important to characterize the coupling of Gab2 to RTKs expressed in this cell type and implicated in the development of breast cancer. MCF-7 cells were serum-starved and then stimulated for 5 min with either EGF (which activates erbB1 homodimers and erbB1/erbB2 and erbB1/erbB3 heterodimers), heregulin (HRG)b1 (erbB2/erbB3 heterodimers), insulin (10 mg/ml activates both IRs and IGF-IRs) or bFGF (FGFR1 and FGFR2) . Following the preparation of cell lysates, Gab2 was immunoprecipitated and then subjected to Western blot analysis with an anti-phosphotyrosine antibody (Figure 3a) . Tyrosine phosphorylation of Gab2 was markedly increased by the addition of HRGb1, which also increased the tyrosine phosphorylation of two proteins of approximately 50 kDa which co-immunoprecipitated with Gab2. These were subsequently demonstrated by Western blotting to be the 52 and 46 kDa Shc isoforms (Figure 3a) . The other growth factors also increased tyrosine phosphorylation of Gab2, but to a lesser extent. Growth factor treatment also resulted in a variable decrease in mobility of Gab2 upon SDS -PAGE, which is due to serine/threonine, as well as tyrosine, phosphorylation (Lynch and Daly, 2002) . These data demonstrate that Gab2 couples to receptors for a variety of growth factors known to play autocrine and/or paracrine roles in regulation of breast cancer cell proliferation (Hynes, 2000) .
The trend for increased Gab2 expression in ERpositive breast cancer cell lines led us to investigate whether Gab2 was estrogen regulated. MCF-7 breast cancer cells were maintained for 3 days in steroiddepleted medium with or without the addition of estradiol, the pure anti-estrogen ICI 182780, or the two in combination. Estrogen increased the expression of Gab2 protein approximately twofold, the induction being inhibited by ICI 182780, indicating that regulation was mediated via the ER (Figure 3b) . Although an apparent decrease in Gab1 expression occurred upon estrogen treatment, this effect was not reproducible in repeated experiments. Similar experiments in T-47D breast cancer cells revealed a marked upregulation of Figure 3 Gab2 is a target of both growth factor and steroid signaling pathways. (a) Coupling of Gab2 to different RTKs expressed in human breast cancer cells. MCF-7 cells were grown to 70 -80% confluence and then serum-starved overnight in RPMI 1640 medium (Invitrogen) containing 0.5% FCS (Invitrogen). The cells were then stimulated for 5 min with human recombinant EGF (R&D Systems, 100 ng/ml final concentration), HRGb1 (R&D Systems, 80 ng/ml), insulin (Novo Nordisk Pharmaceuticals, 10 mg/ml) or bFGF (50 ng/ml) . Following preparation of cell lysates, immunoprecipitations were performed as described previously (Janes et al., 1994) , except that protein G-sepharose (Zymed) was used to isolate the goat antibody complexes. The Gab2 immunoprecipitates (IP) were then subjected to Western blot analysis with antibodies against phosphotyrosine (P-Tyr) (Transduction Laboratories RC20, E120H), Shc (Transduction Laboratories S14630), or Gab2. Positions of molecular weight markers are indicated. (b) Gab2 expression is estrogen regulated in hormone-responsive breast cancer cells. MCF-7 or T-47D cells were plated in 10 cm tissue culture dishes (Falcon) (5610 5 cells per dish) in RPMI 1640 medium supplemented with 10% FCS and 10 mg/ml insulin (10N RPMI). The following day the medium was changed to phenol red-free RPMI 1640 medium supplemented with 10% charcoal-stripped fetal calf serum, with drug additions where appropriate, and the cells were harvested 3 days later. Cell lysates were prepared from cells maintained under steroid-depleted conditions (C) or supplemented with estradiol (1 nM, E), ICI 182780 (100 nM, ICI), or the two treatments in combination (E/ICI). Each treatment utilized the same volume of ethanol vehicle. Equivalent amounts of cell lysate (40 mg protein) were then subjected to Western blot analysis with antibodies specific for Gab2 (top panel), Gab1 (middle panel) or actin (bottom panel). Visualization of bound antibodies was by ECL. The apparent small increase in Gab2 expression upon anti-estrogen treatment of T-47D cells was not reproducible Gab2 by estrogen (Figure 3b ), while Gab1 expression was not altered. These results suggest that estrogen regulation of Gab2 expression is common to ERpositive breast cancer cell lines, and indicate that the two family members, Gab1 and Gab2, differ in their response to this steroid.
In order to characterize the kinetics of regulation of GAB2 gene expression by estradiol and the underlying mechanism, we utilized an 'estrogen rescue' model in which MCF-7 cells are arrested in G1 phase by treatment with ICI 182780 and then stimulated to reenter the cell cycle by estradiol (Prall et al., 1997) . Gab2 expression was increased approximately twofold following 6 h of estrogen treatment and a maximal induction of 3 -4-fold relative to controls was attained at 12 h (Figure 4a ). Northern blot analysis for GAB2 expression in MCF-7 cells maintained for 3 days in estrogen-supplemented or deprived conditions demonstrated that the estrogen stimulation of Gab2 protein expression was accompanied by a similar regulation of GAB2 mRNA (data not shown). This was investigated further in the estrogen rescue model. Northern blot analysis of RNA samples prepared in parallel with a subset of the protein lysate samples analysed in Figure  4a revealed that GAB2 mRNA expression was downregulated 3.5-fold by ICI 182780 treatment and restored to maximal levels following 6 h of estrogen rescue (Figure 4b ). These data demonstrate that regulation of GAB2 expression by estrogen in MCF-7 cells is primarily at the mRNA level.
Since estrogen stimulates anti-estrogen-arrested MCF-7 cells to re-enter the cell cycle (Prall et al., 1997) , the increase in Gab2 expression induced upon estrogen rescue could be related to cell cycle progression rather than hormone treatment. In order to resolve this issue, we utilized a model involving MCF-7 cells transfected with a construct encoding cMyc under the control of the metal response elements of the hMTIIA promoter (Prall et al., 1998) . In this system, induction of c-Myc expression by Zn treatment is sufficient to induce anti-estrogen-arrested cells to reenter the cell cycle. Cells were arrested by ICI 182780 treatment and then stimulated with either estrogen or Zn. Estrogen induced c-Myc in both MCF-7/DMT control cells and MCF-7/DMT-c-Myc cells at 6 h, whereas Zn only induced c-Myc in the DMT-c-Myc transfectants (data not shown). As expected, estrogen induced both cell types to re-enter the cell cycle, resulting in an increase in S phase fraction from 4.2 to 39% for MCF-7/DMT cells and from 5.9 to 41% for MCF-7/DMT-c-Myc cells. However, Zn significantly increased the percentage of cells in S phase only in the MCF-7/DMT-c-Myc line (to 21, compared with 7.3% for MCF-7/DMT). Western blotting revealed that Gab2 expression was increased at both 24 and 48 h following estrogen treatment of either cell type, but remained unchanged following Zn addition, despite the significant cell cycle progression of the MCF-7/DMT-cMyc cells (Figure 4c) . We attribute the more marked regulation of Gab2 observed in these cell lines at the 48 h time points compared with parental MCF-7s Figure 4 Kinetics and mechanism of regulation of GAB2 gene expression by estradiol. (a) Time course of regulation of Gab2 protein levels by estradiol. MCF-7 cells were plated in 10 cm tissue culture dishes (5610 5 cells per dish) in 10N RPMI. The next day, ICI 182780 (10 nM) was added and the cells maintained in the presence of the anti-estrogen for 2 days. The cells were then induced to re-enter the cell cycle by the addition of estradiol (100 nM) to the culture medium and harvested for RNA or protein isolation at different time points. Cell lysates were then Western blotted for either Gab2 or actin. Lysates from cells maintained in estrogen-containing medium were included for comparison (10N). Each lane contained 40 mg protein. (b) Regulation of GAB2 expression by estrogen is at the mRNA level. Samples of total RNA prepared in parallel to the protein samples described in (a) were subjected to Northern blot analysis with a 32 P-labeled GAB2 cDNA probe. Each lane contained 20 mg total RNA. The blot was then re-probed with a 220 bp PstI restriction fragment from the 36B4 cDNA, which encodes a ribosomal protein (Laborda, 1991) . (c) Dissociation of estrogen regulation of Gab2 expression from cell cycle progression. MCF-7 cell lines stably transfected with the vector pDMT-c-Myc, in which expression of c-Myc is regulated by Zn-responsive elements of the hMTIIA promoter, or the control plasmid pDMT, were generated as previously described (Prall et al., 1998) . MCF-7/DMT-c-Myc and MCF-7/DMT cell lines were subjected to ICI 182780-induced cell cycle arrest as described above, and then treated with either ethanol vehicle (C), estradiol (100 nM) (E) or ZnSO 4 (65 mM) (Zn) in the presence or absence of nocodazole (50 ng/ml). Cells were then harvested 24 and 48 h later for either protein isolation or FACS. The latter analysis was performed as previously described (Prall et al., 1998) . Cell lysates were Western blotted for either Gab2 or actin. Forty mg of protein were loaded per lane. Note that although both estrogen and Zn stimulation induce cell cycle progression in MCF-7/DMT-c-Myc cells, only estradiol increases Gab2 expression. In the right hand panel, rescue of MCF-7/DMT cells with estradiol and MCF-7/DMT-c-Myc cells with Zn was performed in the presence of nocodazole to induce a G2/M block ( Figure 4a ) to clonal variation. In order to further dissect estrogen treatment from cell cycle effects, cells were pre-treated with nocodazole in order to induce a G2/M phase block following estrogen or Zn rescue. At 48 h following rescue, similar proportions (56 and 59%, respectively) of estrogen-treated MCF-7/DMT and Zn-treated MCF-7/DMT-c-Myc cells were arrested in G2/M. However, when Gab2 expression was determined for the two cell populations, it was high for the cells exposed to estrogen, and very low for those treated with Zn (Figure 4c ).
These experiments demonstrate that estrogen treatment, but not cell cycle progression per se, increases Gab2 expression in MCF-7 cells. Furthermore, although estrogen increases c-Myc expression in this cell line (Prall et al., 1997) , these data also reveal that induction of c-Myc alone is insufficient to reproduce the effect of estrogen on GAB2 gene expression.
Strong genetic and biochemical evidence supports an important role for the Gab/DOS family in regulating RTK signaling. Functional analyses also indicate that increased expression of these proteins can amplify downstream signaling leading to altered biological responses. For example, overexpression of either Gab1 or Gab2 can increase growth factor or cytokine-induced Erk activation (Gu et al., 1998; Zhao et al., 1999) and upregulation of Gab1 enhances EGFor insulin-stimulated fibroblast proliferation (HolgadoMadruga et al., 1996) and is sufficient to induce branching morphogenesis of MDCK cells (Weidner et al., 1996) . Despite these findings, the data showing increased expression of Gab2 in a subset of breast cancer cell lines (Figure 1 ) and primary breast cancers (Figure 2 ) represent the first demonstration of overexpression of a Gab family docking protein in a human cancer. However, expression of a Gab1 variant lacking the PH domain was recently correlated with neoplastic progression in a hamster embryo cell transformation system and transfection of an expression construct encoding the truncated, but not full-length, Gab1, enhanced EGF-induced colony formation (Kameda et al., 2001) . In this context it is interesting that MDA-MB-134 cells also expressed relatively high levels of a smaller protein of approximately 90 kDa which reacted with the anti-Gab1 antibody (Figure 1a) . Upon longer exposures, this band was also detected in most of the other cell lines expressing Gab1. The size of this protein is consistent with the Gab1 variant, but further experimentation will be required to confirm this assignment.
Most work on Gab2 signaling published to date has centred on hematopoietic cells, with Gab2 tyrosine phosphorylation evoked by stimuli such as T and B-cell receptor stimulation or addition of CSF-1, IL-2 or IL-3 (Gu et al., 1998) . Considering the high expression of Gab2 in some breast cancers, it was important to demonstrate a role for this docking protein in signaling by growth factor receptors implicated in the pathophysiology of this disease. Although Gab2 tyrosine phosphorylation was induced by EGF, insulin, bFGF and HRG, the response to the latter growth factor was particularly marked. This is of interest since although the docking proteins IRS-1 and IRS-2 are also estrogen regulated (Lee et al., 1999) , they are tyrosine phosphorylated in response to insulin, IGFs or certain cytokines e.g. IL-4 (Yenush and White, 1997) . In MCF-7 cells, HRG preferentially signals via erbB2/ erbB3 heterodimers (Tzahar et al., 1996) . Gab2 therefore represents a novel site of interplay between steroid and erbB receptor signaling. We also observed strong association of tyrosine-phosphorylated Shc with Gab2 following HRG stimulation (Figure 3a) . This may reflect bridging of Gab2 to activated erbB receptors via a Shc/Grb2 complex, since Shc, which is a major substrate of erbB receptors, binds in its tyrosinephosphorylated form to the SH2 domain of Grb2, which in turn, binds Gab2 via its SH3 domains (Zhao et al., 1999; Rozakis-Adcock et al., 1992) . This mechanism of Gab2 recruitment has recently been described for the IL3 receptor beta common chain (Gu et al., 2000) .
Gab2 was clearly overexpressed in a subset of breast cancer cell lines compared to normal breast epithelial cell strains, while Gab1 expression was generally high in both cell types (Figure 1 ). There was also a trend for increased expression of Gab2 in ER-positive lines, while this was not evident for Gab1. Finally, a functional consequence of this correlation was revealed by the observation that GAB2 expression was regulated at both the mRNA and protein level by estradiol (Figures 3b and 4) , whereas Gab1 expression was unaffected by estrogen treatment of MCF-7 or T-47D cells. The contrasting expression pattern and regulation of Gab1 and Gab2 in breast cancer cells is consistent with a growing body of evidence suggesting that these two proteins are not functionally redundant. Opposing effects on Elk-1-mediated transcription have been reported for these two docking proteins (Zhao et al., 1999) , and the phenotypes of the respective gene knock-out mice are strikingly different. Gab1 7/7 mice die in utero due to defective Erk signaling (Itoh et al., 2000) , whereas Gab2 7/7 mice exhibit an impaired allergic response due to defective activation of the PI3-kinase pathway following activation of the mast cell FceRI receptor (Gu et al., 2001) . However, Erk activation in bone marrow-derived mast cells from Gab2 7/7 mice is unimpaired. Further definition of the signal output from Gab1 and Gab2 will shed light on the functional consequences of their different expression patterns among breast cancer cell lines and their contrasting regulation in estrogen-responsive cells.
Overall this study highlights the multiple levels at which the steroid and growth factor signaling systems interact in breast cancer. Estrogens regulate not only the expression of specific growth factors (e.g. TGF-a, IGF-II), IGF binding proteins and RTKs (e.g. IGF-IR), but also intracellular signaling intermediates (e.g. the docking proteins IRS-1, IRS-2 and as demonstrated here, Gab2) (Bates et al., 1988; Yee and Lee, 2000; Lee et al., 1999) . An interesting question is whether constitutive overexpression of such proteins might lead to steroid autonomy, generally regarded as an early step in the development of anti-estrogen resistance. In this context it is worth noting that overexpression of IGF-II or IRS-1 in MCF-7 cells leads to decreased estrogen sensitivity (Daly et al., 1991; Cullen et al., 1992; Surmacz and Burgaud, 1995) . Interestingly, in a study of 200 node negative breast cancer patients, high expression of IRS-1 correlated with ER positivity and in a subset with small tumors, decreased disease-free survival (Rocha et al., 1997) . IRS-1 expression has also been correlated with early disease recurrence in ER-positive breast cancer patients (Lee et al., 1999) . It will therefore be of interest to examine the relationship between the expression of Gab2 and patient prognosis, and to determine whether altered expression of estrogen-regulated docking proteins affects response rates to anti-estrogen therapy in breast cancer patients.
